



## **argenx to Present at 43<sup>rd</sup> Annual J.P. Morgan Healthcare Conference**

**January 6, 2025**

**Amsterdam, the Netherlands** – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 43<sup>rd</sup> Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:45 a.m. PT.

A live webcast of the presentation may be accessed on the Investors section of the argenx website at [argenx.com/investors](https://www.argenx.com/investors). A replay of the webcast will be available on the argenx website for approximately 30 days following the presentation.

### **About argenx**

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, globally in the U.S., Japan, Israel, the EU, the UK, China and Canada. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit [www.argenx.com](https://www.argenx.com) and follow us on [LinkedIn](#), [X/Twitter](#), [Instagram](#), [Facebook](#), and [YouTube](#).

**For further information, please contact:**

#### **Media:**

Ben Petok  
bpetok@argenx.com

#### **Investors:**

Alexandra Roy (US)  
aroy@argenx.com

Lynn Elton (EU)  
lelton@argenx.com